{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:50:48Z","timestamp":1790070648825,"version":"4.0.1"},"reference-count":18,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Randomized clinical trials remain the gold standard to establish efficacy and safety of new treatments. In acute myeloid leukemia, large trials have been associated with gradual improvement in outcome over 2 decades in younger patients without major differences emerging between treatments. By contrast, in older patients, improvement has been minimal, which justifies a new approach to identifying effective treatments. Given the urgent unmet need, and with the emergence of several novel agents or combinations that are likely to be expensive, large benefits are probably required to change clinical practice. To address this issue, we have evolved a \u201cPick a Winner\u201d randomized progressive design with a rolling incorporation of novel treatments (drug X), which has been tested in older patients with acute myeloid leukemia. The rationale, operational characteristics, and initial experience of such an approach in the context of the United Kingdom National Cancer Research Institute AML16 trial are presented.<\/jats:p>","DOI":"10.1182\/blood-2011-02-337261","type":"journal-article","created":{"date-parts":[[2011,7,7]],"date-time":"2011-07-07T05:34:51Z","timestamp":1310016891000},"page":"2389-2394","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":74,"title":["Applicability of a \u201cPick a Winner\u201d trial design to acute myeloid leukemia"],"prefix":"10.1182","volume":"118","author":[{"given":"Robert K.","family":"Hills","sequence":"first","affiliation":[{"name":"Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan K.","family":"Burnett","sequence":"additional","affiliation":[{"name":"Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"18","key":"2019111807470024200_B1","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"14","key":"2019111807470024200_B2","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archinte.162.14.1597","article-title":"The outcomes and costs of acute myeloid leukemia among the elderly.","volume":"162","author":"Menzin","year":"2002","journal-title":"Arch Intern Med"},{"issue":"14","key":"2019111807470024200_B3","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","article-title":"Acute myeloid leukemia.","volume":"341","author":"Lowenberg","year":"1999","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111807470024200_B4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia.","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111807470024200_B5","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/djn267","article-title":"Speeding up the evaluation of new agents in cancer.","volume":"100","author":"Parmar","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"2019111807470024200_B6","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2010-05-285387","article-title":"Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.","volume":"116","author":"Walter","year":"2010","journal-title":"Blood"},{"issue":"14","key":"2019111807470024200_B7","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/sim.1430","article-title":"Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer.","volume":"22","author":"Royston","year":"2003","journal-title":"Stat Med"},{"issue":"7","key":"2019111807470024200_B8","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/sim.704","article-title":"A flexible design for multiple armed screening trials.","volume":"20","author":"Sargent","year":"2001","journal-title":"Stat Med"},{"issue":"9","key":"2019111807470024200_B9","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia.","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2019111807470024200_B10","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome.","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"2019111807470024200_B11","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"issue":"11","key":"2019111807470024200_B12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2962.2962","article-title":"Low dose Ara-C versus low dose Ara-C and tipifarnib: result of the UK NCRI AML16 \u201cPick a Winner\u201d comparison [abstract].","volume":"112","author":"Burnett","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2019111807470024200_B13","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2011.59","article-title":"The addition of arsenic trioxide to low dose Ara-C in elderly patients with AML does not improve outcome.","volume":"25","author":"Burnett","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"2019111807470024200_B14","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.","volume":"28","author":"Cashen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111807470024200_B15","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111807470024200_B16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019111807470024200_B17","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.18.18","article-title":"The addition of gemtuzumab ozogamicin to low dose Ara-C improves remission rates but not survival: results of the UK LRF AML14 and NCRI AML16 \u201cPick a Winner\u201d comparison [abstract].","volume":"116","author":"Burnett","year":"2010","journal-title":"Blood"},{"key":"2019111807470024200_B18","unstructured":"Measuring effectiveness and cost effectiveness: the QALY. Accessed February 9, 2011 http:\/\/www.nice.org.uk\/newsroom\/features\/measuringeffectivenessandcosteffectivenesstheqaly.jsp"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/9\/2389\/1347931\/zh803511002389.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/9\/2389\/1347931\/zh803511002389.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T05:29:21Z","timestamp":1592717361000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/9\/2389\/29484\/Applicability-of-a-Pick-a-Winner-trial-design-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,1]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-02-337261","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,1]]}}}